Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 454

1.

Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.

Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH.

World J Gastroenterol. 2014 Jan 21;20(3):745-54. doi: 10.3748/wjg.v20.i3.745.

2.

Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF.

World J Gastroenterol. 2014 Dec 14;20(46):17483-90. doi: 10.3748/wjg.v20.i46.17483.

3.

Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.

Zhang DZ, Wei XD, Wang XP.

World J Gastroenterol. 2015 Apr 21;21(15):4635-43. doi: 10.3748/wjg.v21.i15.4635.

4.

Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.

Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z.

J Vasc Interv Radiol. 2016 Dec;27(12):1829-1836. doi: 10.1016/j.jvir.2016.06.010. Epub 2016 Aug 21.

PMID:
27553917
5.

Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.

J Vasc Interv Radiol. 2013 Mar;24(3):307-15. doi: 10.1016/j.jvir.2012.11.026. Epub 2013 Jan 29.

PMID:
23375519
6.

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.

Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS.

Clin Mol Hepatol. 2017 Mar;23(1):42-50. doi: 10.3350/cmh.2016.0058. Epub 2017 Mar 7.

7.

Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?

Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, Minqing X, Jiaying Y.

Medicine (Baltimore). 2014 Nov;93(26):e180. doi: 10.1097/MD.0000000000000180.

8.

Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.

Li HL, Ji WB, Zhao R, Duan WD, Chen YW, Wang XQ, Yu Q, Luo Y, Dong JH.

World J Gastroenterol. 2015 Mar 28;21(12):3599-606. doi: 10.3748/wjg.v21.i12.3599.

9.

Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.

Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY.

Liver Int. 2014 Apr;34(4):612-20. doi: 10.1111/liv.12307. Epub 2013 Sep 13.

PMID:
24028297
10.

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.

Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ, Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR, Xiang BD.

World J Gastroenterol. 2015 Apr 21;21(15):4627-34. doi: 10.3748/wjg.v21.i15.4627.

11.

Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.

Chen RX, Gan YH, Ge NL, Chen Y, Ma H, Wang Y, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG.

J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077.

PMID:
26259976
12.

Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.

Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ.

Ann Surg Oncol. 2014 Sep;21(9):3069-76. doi: 10.1245/s10434-014-3704-8. Epub 2014 Apr 12.

PMID:
24728740
13.

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.

Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK.

Korean J Intern Med. 2016 Mar;31(2):242-52. doi: 10.3904/kjim.2015.112. Epub 2016 Feb 15.

14.
15.

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT.

Gastroenterology. 2014 Jun;146(7):1691-700.e3. doi: 10.1053/j.gastro.2014.02.032. Epub 2014 Feb 25.

PMID:
24583061
16.

Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.

Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD, Li LQ.

World J Gastroenterol. 2014 Dec 7;20(45):17141-7. doi: 10.3748/wjg.v20.i45.17141.

17.

A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.

Chen L, Ni CF, Chen SX, Cao JM, Zhu HD, Guo JH, Zhu GY, Zhong BY, Ding W, He SC, Deng G, Teng GJ.

J Vasc Interv Radiol. 2016 Sep;27(9):1288-1297. doi: 10.1016/j.jvir.2015.12.016. Epub 2016 Mar 21.

PMID:
27013402
18.

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W.

Radiology. 2012 May;263(2):590-9. doi: 10.1148/radiol.12111550. Epub 2012 Mar 21.

PMID:
22438359
19.

Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.

Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ.

PLoS One. 2013 Jul 9;8(7):e68193. doi: 10.1371/journal.pone.0068193. Print 2013.

20.

Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.

Huang Y, Chen B, Liu N, Li N, Dao H, Chen W, Yang J.

Int J Clin Pharmacol Ther. 2017 Jun;55(6):498-508. doi: 10.5414/CP202787.

PMID:
28157070

Supplemental Content

Support Center